HVTN 505

HVTN 505 is a clinical trial that was conducted to evaluate the efficacy of a HIV vaccine candidate. The trial was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and was managed by the HIV Vaccine Trials Network (HVTN).

Overview

The HVTN 505 trial was a phase IIb, randomized, double-blind, placebo-controlled trial. It was designed to evaluate the safety, immunogenicity, and efficacy of a DNA prime-recombinant adenovirus type 5 boost vaccine regimen in preventing HIV-1 infection or reducing viral load set point in participants who became infected with HIV-1 during the trial.

Trial Design

The trial enrolled 2,504 men who have sex with men and transgender people who have sex with men in 19 cities across the United States. Participants were randomly assigned to receive either the vaccine regimen or a placebo. The vaccine regimen consisted of a series of injections: a DNA-based vaccine at the start of the study and after 1 and 2 months, followed by a recombinant adenovirus type 5 boost at 6 months.

Results

The trial was stopped early in 2013 after an interim analysis showed that the vaccine regimen did not prevent HIV infection or reduce viral load in vaccine recipients who became infected with HIV. The trial found no significant difference in the rate of HIV infection between the vaccine and placebo groups.

Implications

The results of the HVTN 505 trial have important implications for future HIV vaccine research. They underscore the complexity of developing an effective HIV vaccine and highlight the need for continued research and innovation in this area.

See Also

• HIV Vaccine Trials Network
• National Institute of Allergy and Infectious Diseases
• National Institutes of Health
• HIV vaccine

This article is a stub related to pharmacology. You can help WikiMD by expanding it!